Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

By D. V. Von Hoff, T. Ervin, F. Arena, E. Chiorean, J. Infante, M. Moore, T. Seay, S. Tjulandin, W. Ma, M. Saleh and 13 more. New England Journal of Medicine, 2013

5,951 citations recorded by the source corpus.

Subfields: Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/8a05f730ab8794a78a400c895d2f37d65bf499ec

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. W. Hawkins
2. J. Seoane
3. Hans Clevers
4. D. Propper
5. D. Tuveson
6. Zhesheng Chen
7. Japanese Gastric Cancer Association
8. Zena Werb

In Surgery

1. Hans Clevers
2. Jennifer J. Knox

Citations in the corpus

• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions (2017, background): “CT is an option for inoperable pancreatic cancer but is associated with high morbidity and although significant, only minor improvement of survival [230].”
• A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (2018, background): “Burris 3RD HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas can”
• Organoid profiling identifies common responders to chemotherapy in pancreatic cancer (2018, background): “Therapeutic options for these patients include the combination chemotherapy 99 regimens Gemcitabine/nab-Paclitaxel (6) or FOLFIRINOX (5-Fluorouracil, Leucovorin, Irinotecan, 100 Oxaliplatin) (7).”
• A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy (2016, background): “Also, albumin-bound paclitaxel (ABRAXANE) has been approved for use in combination with gemcitabine as first-line treatment for metastatic pancreatic cancer.(4) Whether the SIRI could be used for predicting survival in this situation remains unclear because of limited clinical data.”
• A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “610,83) 5% gain at 24 mth 3 [149]”